Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: B.REVERE who wrote (381)	6/22/1998 1:01:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Thanks, BR. Sorry for posting the Furman thing twice, intended to post the Cowen upgrade, and somehow messed up in my cut and paste. I'm watching out for the new scripts.

To: B.REVERE who wrote (381)	6/22/1998 1:25:00 PM
From: Anthony Wong	Respond to of 1722

From AP - Switzerland Approves Sale of Viagra JUNE 22, 10:08 EDT BERN, Switzerland (AP) - Swiss authorities Monday approved sale of the potency pill Viagra, adding Switzerland to tiny San Marino and Andorra as European countries where the drug can be bought legally. The Intercantonal Office for the Control of Medicine said it was requiring a prescription for the pill because it is necessary to follow directions carefully to limit problems with side effects. As elsewhere in Europe, Swiss news media have shown strong interest in Viagra since it was introduced in the United States earlier this year. Demand for Viagra has far outstripped supply in San Marino, a mountain republic in eastern Italy that approved its sale within days of its U.S. debut in April. Demand has also been high in Andorra, sandwiched between Spain and France. Manufacturer Pfizer expects approval for sale in the 15-nation European Union early next year.

To: B.REVERE who wrote (381)	6/22/1998 1:53:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

The pharmaceutical analyst from Hambrest and Quist was interviewed on CNBC by Sue Herera around half an hour ago. He was still bullish on the drug group - few Asian exposure, good defensive play etc, though the group was quite expensive. Particularly liked Merck and Johnson & Johnson. On PDA's non approval letter on Zeldox. He had no further information as to details. Thought FDA was walking on egg shells after the incidents of drugs such as WLA's Rezulin and today's AHP's withdrwal of Duract. He thought Zeldox's approval might be delayed to next summer, but that it won't hurt Pfizer, what with Viagra being approved later this year in Europe and their strong drug pipeline. He still thinks Pfizer is a buy.